AAP
AQST icon

Arax Advisory Partners’s Aquestive Therapeutics AQST Stock Holding History

Arax Advisory Partners’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.84K Buy
+2,125
New +$8.94K ﹤0.01% 4385
2026
Q1 		– Sell
-7
Closed -$45 – 3804
2025
Q4 		$45 Sell
7
-161
-96% -$1K ﹤0.01% 3932
2025
Q3 		$939 Buy
+168
New +$726 ﹤0.01% 3268

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Arax Advisory Partners's AQST Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Aquestive Therapeutics (AQST) in Q2 2026: 2,125 shares worth $8.84K. The stake represents ﹤0.01% of the portfolio and ranks #4385 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in AQST as recently as Q4 2025.

Arax Advisory Partners first reported a position in AQST in Q3 2025 and has held it in 3 quarters since. 184 funds tracked by Wall St. Rank hold AQST as of Q2 2026.

  • Arax Advisory Partners held 2,125 shares of Aquestive Therapeutics worth $8.84K as of Q2 2026.
  • Aquestive Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Aquestive Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4385 holding.
  • Arax Advisory Partners first reported a position in Aquestive Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 184 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.